Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
$18.02
+6.3%
$21.58
$15.47
$36.37
$687.64M1.17281,266 shs543,062 shs
Journey Medical Corporation stock logo
DERM
Journey Medical
$7.25
-15.1%
$7.16
$3.54
$8.90
$198.95M0.8148,083 shs484,841 shs
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
$1.93
-4.0%
$1.90
$1.33
$2.36
$59.44M1.76173,085 shs236,916 shs
Mind Medicine (MindMed) Inc. stock logo
MNMD
Mind Medicine (MindMed)
$9.97
-1.8%
$8.22
$4.70
$10.49
$772.29M2.491.32 million shs1.04 million shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
+6.31%-5.61%-17.60%-6.34%-22.03%
Journey Medical Corporation stock logo
DERM
Journey Medical
-15.11%+0.28%-2.16%+2.11%+50.41%
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
-3.98%+2.66%-1.53%+8.43%+5.46%
Mind Medicine (MindMed) Inc. stock logo
MNMD
Mind Medicine (MindMed)
-1.77%+0.81%+19.69%+52.21%+51.29%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
1.9074 of 5 stars
4.60.00.00.01.70.80.0
Journey Medical Corporation stock logo
DERM
Journey Medical
1.6537 of 5 stars
3.51.00.00.01.60.80.6
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
2.6176 of 5 stars
3.51.00.00.02.43.30.6
Mind Medicine (MindMed) Inc. stock logo
MNMD
Mind Medicine (MindMed)
2.0903 of 5 stars
3.61.00.00.02.80.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
3.14
Buy$39.14117.22% Upside
Journey Medical Corporation stock logo
DERM
Journey Medical
3.00
Buy$10.8349.43% Upside
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
3.00
Buy$21.00988.08% Upside
Mind Medicine (MindMed) Inc. stock logo
MNMD
Mind Medicine (MindMed)
3.22
Buy$24.71147.89% Upside

Current Analyst Ratings Breakdown

Latest DERM, FBIO, AVBP, and MNMD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/13/2025
Journey Medical Corporation stock logo
DERM
Journey Medical
Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$9.00 ➝ $13.00
8/12/2025
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$40.00 ➝ $42.00
8/12/2025
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$40.00 ➝ $33.00
8/4/2025
Mind Medicine (MindMed) Inc. stock logo
MNMD
Mind Medicine (MindMed)
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$25.00
8/1/2025
Mind Medicine (MindMed) Inc. stock logo
MNMD
Mind Medicine (MindMed)
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00
7/22/2025
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$40.00
7/10/2025
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeBuy$33.00
6/24/2025
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$39.00 ➝ $44.00
6/24/2025
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$45.00
5/20/2025
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
Jones Trading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$40.00
5/15/2025
Journey Medical Corporation stock logo
DERM
Journey Medical
Alliance Global Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
(Data available from 8/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
N/AN/AN/AN/A$6.16 per shareN/A
Journey Medical Corporation stock logo
DERM
Journey Medical
$56.13M3.01N/AN/A$0.91 per share7.97
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
$57.67M0.99N/AN/A($0.06) per share-32.17
Mind Medicine (MindMed) Inc. stock logo
MNMD
Mind Medicine (MindMed)
N/AN/AN/AN/A$2.44 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
-$80.49M-$3.77N/AN/AN/AN/A-55.40%-51.97%8/13/2025 (Estimated)
Journey Medical Corporation stock logo
DERM
Journey Medical
-$14.67M-$0.39N/AN/AN/A-15.49%-49.90%-11.44%N/A
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
-$46M-$2.23N/AN/AN/A-71.24%-4,712.53%-27.67%N/A
Mind Medicine (MindMed) Inc. stock logo
MNMD
Mind Medicine (MindMed)
-$108.68M-$1.53N/AN/AN/AN/A-50.24%-39.41%N/A

Latest DERM, FBIO, AVBP, and MNMD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2025Q2 2025
Journey Medical Corporation stock logo
DERM
Journey Medical
-$0.07-$0.16-$0.09-$0.16$14.93 million$15.01 million
8/11/2025Q2 2025
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
-$0.70-$0.90-$0.20-$0.90N/AN/A
7/31/2025Q2 2025
Mind Medicine (MindMed) Inc. stock logo
MNMD
Mind Medicine (MindMed)
-$0.38-$0.50-$0.12-$0.50N/AN/A
5/14/2025Q1 2025
Journey Medical Corporation stock logo
DERM
Journey Medical
-$0.24-$0.18+$0.06-$0.18$12.05 million$13.14 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
N/AN/AN/AN/AN/A
Journey Medical Corporation stock logo
DERM
Journey Medical
N/AN/AN/AN/AN/A
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
N/AN/AN/AN/AN/A
Mind Medicine (MindMed) Inc. stock logo
MNMD
Mind Medicine (MindMed)
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
N/A
12.74
14.34
Journey Medical Corporation stock logo
DERM
Journey Medical
1.07
1.34
1.03
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
1.74
1.72
1.55
Mind Medicine (MindMed) Inc. stock logo
MNMD
Mind Medicine (MindMed)
0.22
4.98
4.98

Institutional Ownership

CompanyInstitutional Ownership
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
9.48%
Journey Medical Corporation stock logo
DERM
Journey Medical
7.25%
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
96.51%
Mind Medicine (MindMed) Inc. stock logo
MNMD
Mind Medicine (MindMed)
27.91%

Insider Ownership

CompanyInsider Ownership
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
18.58%
Journey Medical Corporation stock logo
DERM
Journey Medical
15.03%
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
27.90%
Mind Medicine (MindMed) Inc. stock logo
MNMD
Mind Medicine (MindMed)
2.45%
CompanyEmployeesShares OutstandingFree FloatOptionable
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
4040.57 million27.86 millionN/A
Journey Medical Corporation stock logo
DERM
Journey Medical
9023.30 million19.80 millionN/A
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
17029.57 million21.32 millionOptionable
Mind Medicine (MindMed) Inc. stock logo
MNMD
Mind Medicine (MindMed)
4076.09 million74.22 millionOptionable

Recent News About These Companies

Research Analysts Issue Forecasts for MNMD Q3 Earnings
1 Reason to Buy MindMed (MNMD)
HC Wainwright Has Positive Estimate for MNMD FY2028 Earnings
Roth Capital Issues Pessimistic Forecast for MNMD Earnings
Is Mind Medicine stock a buy?
MindMed (MNMD) Q2 Net Loss Jumps 625%

New MarketBeat Followers Over Time

Media Sentiment Over Time

ArriVent BioPharma stock logo

ArriVent BioPharma NASDAQ:AVBP

$18.02 +1.07 (+6.31%)
Closing price 08/13/2025 04:00 PM Eastern
Extended Trading
$18.00 -0.02 (-0.11%)
As of 08/13/2025 05:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

Journey Medical stock logo

Journey Medical NASDAQ:DERM

$7.25 -1.29 (-15.11%)
Closing price 08/13/2025 04:00 PM Eastern
Extended Trading
$7.80 +0.56 (+7.66%)
As of 08/13/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.

Fortress Biotech stock logo

Fortress Biotech NASDAQ:FBIO

$1.93 -0.08 (-3.98%)
Closing price 08/13/2025 04:00 PM Eastern
Extended Trading
$1.96 +0.03 (+1.55%)
As of 08/13/2025 07:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

Mind Medicine (MindMed) stock logo

Mind Medicine (MindMed) NASDAQ:MNMD

$9.97 -0.18 (-1.77%)
Closing price 08/13/2025 04:00 PM Eastern
Extended Trading
$9.99 +0.02 (+0.24%)
As of 08/13/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.